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Abstract  
Background: Life expectancy is reduced by 19 years in men and 17 in women with psychosis 
in Sweden, largely due to cardiovascular disease. 
Aim: Assess whether a psychosocial health promotion intervention improves cardiometabolic 
risk factors, quality of life, and severity of illness in patients with psychotic disorders more 
than treatment as usual.  
Methods: A pragmatic intervention trial testing a manual-based multi-component health 
promotion intervention targeting patients with psychosis. The Swedish intervention was 
adapted from IMPaCT therapy, a health-promotion program based on motivational 
interviewing and cognitive behavioral therapy, designed to be incorporated into routine care. 
The intervention group consisted of 119 patients and a control group of 570 patients from 
specialized psychosis departments. Outcome variables were assessed 6 months before 
intervention during the run-in period, again at the start of intervention, and 12 months after 
the intervention began. The control group received treatment as usual.  
Results: The intervention had no significant effect on any of the outcome variables. However, 
BMI, waist circumference, systolic BP, heart rate, HbA1c, general health, and Clinical Global 
Impressions Scale score improved significantly during the run-in period before the start of the 
active intervention (observer effect). The multi-component design meant that treatment effects 
could only be calculated for the intervention as a whole. 
Conclusion: The results of the intervention are similar to those of the U.K. IMPaCT study, in 
which the modular health-promotion intervention had little effect on cardiovascular risk 
indicators. However, in the current study, the run-in period had a positive effect on 
cardiometabolic risk factors. 
 
 
Keywords: cardiovascular risk factors, lifestyle intervention, psychiatric care, mental health, 
psychosis, run-in period. 
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1. INTRODUCTION  
People with schizophrenia or other psychotic disorders have higher risk for cardiovascular 
disease (CVD) than the general population (Correll et al., 2017). Their diets are poor, they 
exercise less, and they are often overweight/obese and/or smokers (Gardner-Sood et al., 2015; 
Jakobsen et al., 2018; Vancampfort et al., 2017). Metabolic risk factors for CVD, such as 
central obesity, glucose dysregulation, hypertension, and dyslipidemia are highly prevalent in 
people with psychotic disorders (Gardner-Sood et al., 2015; Olsson et al., 2015). Moreover, in 
those who take certain antipsychotics (such as clozapine), glucose dysregulation occurs in 
55% within three months and before a change in weight (Howes et al., 2004). Additionally, 
the mortality rate of people with schizophrenia and other psychotic disorders is higher than 
that of the general population (Hjorthoj et al., 2017; Laursen et al., 2013), mainly because of 
CVD (Westman et al., 2017). A study on the life expectancy of people with psychosis found 
that in Sweden, men with schizophrenia spectrum disorders lived 19 fewer years than men in 
the general population, while women with such disorders lived 17 fewer years than their 
general population peers (Nordentoft et al., 2013).  
 
Historically, the physical health of psychiatric patients has been neglected. Awareness of the 
importance of focusing on physical health in these patients is increasing among members of 
the psychiatric profession, but there is currently no evidence-based method to improve the 
physical health of patients with psychoses (schizophrenia spectrum disorders). We 
hypothesized that addressing lifestyle factors such as weight, smoking, and exercise would 
help reduce the increased exposure to cardiometabolic risk factors. The Metabolic 
Intervention Therapy in Psychosis (MINT) study partially replicated a U.K. intervention 
study, called Improving Physical Health and Reducing Substance Use in Psychosis (IMPaCT) 
study. The U.K. IMPaCT study was designed to improve the physical health of people with 
psychosis through behavioral change, by training care coordinators to use motivational 
interviewing and cognitive behavioral therapy techniques to encourage healthier lifestyle 
choices (Gaughran et al., 2013a).   
 
MINT was one of the first larger controlled intervention studies on this topic in Sweden, and 
together with the U.K. IMPaCT intervention study (Gaughran et al., 2017) it constitutes a 
robust evaluation of the effectiveness of motivational interviewing and cognitive behavioral 
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therapy to improve unhealthy lifestyle habits and well-being in people with psychoses. Our 
specific aim was to assess whether IMPaCT therapy, adapted for use in Sweden, improves 
cardiometabolic measures, self-reported health and quality of life, and psychological 
functioning and severity of illness in patients with psychotic disorders in Sweden more than 
treatment as usual. In addition, we evaluated how those measures and outcomes changed 
during a 6-month run-in period before the start of the intervention.  
 
2. METHOD 
2.1. Study design and setting 
The MINT study partially replicated the IMPaCT health promotion intervention (based on 
motivational intervewing and cognitive behavioral therapy) from the United Kingdom 
(Gaughran et al., 2017).  To test IMPaCT therapy in Sweden, psychosis departments in 
Gothenburg, Kristianstad, Hässleholm, and Malmö were recruited to an existing cohort study, 
the Swedish Study of Metabolic Risks in Psychosis (SMRP). Patients in the control group 
came from the psychiatric clinics originally included in SMRP. Patients in the intervention 
group came from the newly recruited psychiatric clinics. In Sweden, specialized psychosis 
departments are responsible for the treatment of most outpatients in their catchment area who 
have long-term psychotic disorders. The cost of treatment was covered by the Swedish health 
insurance system.  
 
The original IMPaCT health promotion intervention, developed at King’s College, London, 
was a manual-guided intervention designed to be integrated into routine care and delivered by 
care coordinators. These care coordinators received training and supervision in motivational 
interviewing and manual-based cognitive behavioral therapy techniques. The Swedish 
intervention was modeled on the U.K. version; the English-language manual was translated 
into Swedish, and the U.K. research group travelled to Sweden to train the Swedish teams in 
IMPaCT therapy and to collaborate in the development and implementation of the Swedish 
study protocol. The MINT research group maintains close collaboration with the IMPaCT 
research group in the United Kingdom. 
 
2.2. Ethical permission 
MINT was part of SMRP and received ethical approval as such from the Stockholm Regional 
Ethics Review Board (dnr 2011/849-32). MINT was carried out in accordance with the Code 
5 
 
of Ethics of the World Medical Association (Declaration of Helsinki) for experiments 
involving humans. 
 
2.3. Participants 
 
2.3.1. Inclusion and exclusion criteria 
Patients were eligible to participate in MINT if they were 18 years or older and had been 
diagnosed with a psychotic disorder (ICD 10 diagnoses F20-29: Schizophrenia, schizotypal 
and delusional disorders; F31.2: Bipolar affective disorder, current episode manic with 
psychotic symptoms; and F31.5: Bipolar affective disorder, current episode severe depression 
with psychotic symptoms). Exclusion criteria included a) a primary diagnosis of learning 
disability; b) a co-existing physical health problem that would, in the opinion of a medical 
doctor, independently impact cardiometabolic measures and/or substance use habits; c) 
current pregnancy or ≤6 months post-partum; or d) a life-threatening or terminal medical 
condition for which the person already received extensive care. Psychiatric diagnoses were 
confirmed by the treating psychiatrist in accordance with ICD-10 diagnostic criteria. 
 
2.3.2. The intervention group 
To select the intervention group, we involved care coordinators who were permanently 
employed at the intervention departments and had a minimum of four patients. We created a 
list of each care coordinator’s eligible patients, and then a blinded administrator used a 
random number generator to randomly select four to six of the patients of each care 
coordinator. The selected patients were then consecutively invited to take part in MINT. If a 
patient declined to participate, we approached the next patient on the list. Patients in the 
intervention group received the intervention in addition to treatment as usual.  
 
2.3.3. The control group  
The control group consisted of the patients with psychotic disorder from the departments that 
originally participated in SMRP. None of these departments included any patients in the 
intervention group. The patients in the control group received treatment as usual but not 
IMPaCT therapy. 
 
2.4. IMPaCT therapy 
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IMPaCT therapy is described in detail in the protocol for the IMPaCT randomized controlled 
trial that took place in the United Kingdom (Gaughran et al., 2013a) and in the IMPaCT 
Manual, Reference Guide, and patients’ handbook “the Better Health Handbook” (Gaughran 
et al., 2013b), copies of which were given to the participating care coordinators. The materials 
were developed by specialists in psychiatry and tailored to needs of people with psychosis. 
Key messages were reinforced via images and text in the materials and repeated by the care 
coordinators. In the MINT study, the Swedish version of IMPaCT therapy was delivered by 
each patient’s care coordinator. The care coordinators in Sweden participated in a week-long 
educational program about IMPaCT therapy jointly run by the U.K. and Swedish teams. The 
program focused on how to improve lifestyle factors and cardiometabolic outcomes in 
patients with psychotic disorders via motivational interviewing and specific cognitive 
behavioral therapy techniques for psychosis.  
 
The IMPaCT therapy in the United Kingdom consisted of eight modules designed to improve 
physical health and reduce substance use in people with psychosis (Gaughran et al., 2013a). 
IMPaCT therapy in Sweden consisted of six of these eight modules: basic cognitive 
behavioral therapy in mental health, smoking, diabetes, healthy eating, alcohol, and exercise 
(Table 1). The Swedish version of IMPaCT therapy did not include the original U.K. modules 
on cannabis and other drugs. In Sweden, those with a primary diagnosis of substance use 
disorder or mixed diagnoses (e.g., substance use disorder and psychosis) are often treated in 
special addiction units that were not included in this study.  
 
In consultation with their care coordinator, patients participating in MINT chose one or more 
of the modules to focus on during the intervention. During the following 9 to 12 months, they 
met their care coordinator each week to work on the modules they had chosen. Individual 
meetings with care coordinators occurred weekly and lasted approximately 45 minutes. Some 
modules included optional group activities (e.g., exercise, healthy eating). Group activities 
also took place weekly and lasted approximately 60 minutes. In the Swedish intervention, all 
participants took part in the exercise module. In most cases, exercise sessions were led by 
physiotherapists with experience working with psychiatric patients. Care coordinators used 
person-centered motivational interview techniques in the individual and group sessions. 
 
Table 1. IMPaCT health promotion therapy in Sweden. 
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2.5. Therapy supervisors in Sweden 
In MINT, the care coordinators in each participating geographical area were supported by a 
specially selected and trained supervisor. The supervisors received a week of additional 
training from the U.K. IMPaCT team.  
 
2.6 Variables 
2.6.1. Sociodemographic variables 
Sociodemographic variables were gathered by the care coordinator via a questionnaire. These 
variables included age, sex, level of education (dichotomized into college or above and less 
than college). The patient's main psychiatric diagnosis was made in accordance with the 
Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). 
 
2.6.2. Outcome measures 
2.6.2.1 Cardiometabolic and lifestyle measures 
Cardiometabolic and lifestyle measures in the study included diagnosis of diabetes, smoking  
(yes/no, and if yes, number of cigarettes), BMI, central obesity (waist circumference >94 cm 
for European men and >80 cm for European women in accordance with the International 
Diabetes Federation consensus definition of the metabolic syndrome) (International Diabetes 
Federation., 2006), systolic blood pressure, diastolic blood pressure, pulse (heart) rate, 
triglycerides, total cholesterol, high density lipoprotein (HDL) cholesterol, low density 
lipoprotein (LDL) cholesterol, fasting serum glucose, long-term blood glucose control as 
measured by glycated hemoglobin (HbA1c), and tests of liver function (including alanine 
aminotransferase [ALT], alkaline phosphatase [ALP], and gamma-glutamyl transpeptidase 
[GGT]). These measures were assessed by the care coordinator in accordance with standard 
protocols. Other cardiometabolic and lifestyle measures in the study included alcohol 
consumption and self-reported physical activity (sedentary minutes per day and week) and 
sedentary behavior (in minutes per day). Alcohol consumption was assessed with the Alcohol 
Use Disorders Identification Test (AUDIT). AUDIT is a ten-item questionnaire developed by 
the World Health Organization to assess risk of alcohol abuse.  
 
2.6.2.2. Self-reported health and quality of life  
There were three measures of self-reported health and quality of life. The first was the general 
health question, which asks people to rate their general health on a scale from one (“very 
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good”) to five (“very bad”). The second was the visual analog scale (EQ VAS) of the EuroQol 
five dimensions questionnaire (EQ5D). The EQ VAS asks participants to rate their health 
from "the best health you can imagine" to "the worst health you can imagine." The third was 
the index assessment of the EQ5D. This index sums the responses to the five variables on the 
EQ5D. 
 
2.6.2.3. Psychological functioning and severity of illness 
These measures include the Global Assessment of Functioning (GAF) scale score (Endicott et 
al., 1976) and the Clinical Global Impressions (CGI) scale score. A GAF score represents a 
psychiatrist's assessment of a patient's current social, occupational, and psychological 
functioning. The psychiatrist chooses one of eleven numerical ranges (0, 1-10, 11-20, and so 
on, up to 91-100); lower scores indicate worse functioning and higher scores, better 
functioning. The 7-point CGI scale score represents the psychiatrist's assessment of the 
current severity of the patient's illness compared to that of other patients with the same illness. 
Higher scores indicate more severe psychiatric illness. 
 
2.7 Data collection 
Measures were assessed at pre-baseline, at baseline, and post-intervention. To study the 
possible effects of inclusion in the study, pre-baseline measures were taken, in the 
intervention group only, 6 months before the designated start of the intervention. 
Subsequently, during the latter part of the following 6-month period, participating care 
coordinators received training in IMPaCT therapy while patients continued to receive their 
usual care. Baseline measurements were performed before implementation of the intervention. 
The Swedish version of IMPaCT therapy was then implemented and actively supervised for 6 
months.  
 
2.8. Statistical analysis 
The analyses were conducted with SPSS (version 22.0). All variables were summarized with 
standard descriptive statistics, such as frequency, mean, and standard deviation. Categorical 
variables; e.g., group and gender, were analyzed with Pearson's chi-squared test or Fisher’s 
exact test if the expected cell frequency was 5 or less. Changes during the 6-month run-in 
period; that is, between inclusion in the study and the start of the intervention, were analyzed 
with the Student’s t-test for paired observations if the variables were approximately normally 
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distributed. For observations with skewed distributions, the Wilcoxon signed-rank test was 
applied.  
 
The significance level in all analyses was 5% (two-tailed). The researchers and statistician 
who analyzed the outcomes were blind to the treatment group. 
 
The study was powered to detect a weight reduction of 3 kg. Weight reduction of >5% of 
baseline body weight is considered clinically relevant (Stevens et al., 2006). The average 
weight in the study population was 90.5 kg at the start of the study, so a >5% weight loss 
would entail a loss of 4.5 kg.  
 
 
3. RESULTS 
3.1 Patient characteristics 
There were few significant differences between the intervention and control groups at the start 
of the intervention, although the intervention group had higher rates of central obesity; more 
severe psychiatric illness; and lower functioning scores (GAF scores >50) than the control 
group (Table 2). Psychiatric diagnoses differed somewhat between the groups. In the 
intervention group, 88 out of 119 completed all assessments. Of 1020 patients in the SMRP 
study, 570 control patients were followed up for one year. 
 
Table 2. Pre-baseline characteristics of patients in the intervention group (n= 119) and the 
control group (n= 1020) 
 
3.2 Pre-baseline measures 
During the 6 month run-in period before the start of the intervention, there were significant 
improvements in BMI, waist circumference, systolic blood pressure, heart rate, glycated 
hemoglobin (HbA1c), general health, and CGI scores. 
 
Table 3. Changes in the intervention group during the run-in period 6 months before the start 
of the intervention (n= 119). 
 
3.3 Results of the intervention 
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Table 4 shows that there was no difference between the intervention group that received the 
Swedish version of IMPaCT therapy and the control group that received usual care in 
cardiometabolic and lifestyle measures, including smoking, BMI, waist circumference, 
systolic blood pressure, diastolic blood pressure, triglycerides, total cholesterol, HDL 
cholesterol, LDL cholesterol, fasting serum glucose, ALT, ALP, and GGT. Nor was there a 
differential effect on self-reported health, quality of life, psychological functioning, or 
severity of psychiatric illness. Although the difference did not reach statistical significance, 
blood glucose decreased more in the intervention than the control group.  
 
Table 4. Changes in cardiometabolic and lifestyle measures, self-reported health and quality 
of life, and psychological functioning and severity of illness in the intervention group (n= 88) 
and control group (n= 570) between the start and the end of the intervention (IMPaCT 
therapy) 
 
4. DISCUSSION 
4.1. Summary 
IMPaCT therapy did not significantly improve cardiometabolic and lifestyle measures, self-
reported health and quality of life, or psychological functioning and severity of illness in 
patients with psychotic disorders in Sweden more than treatment as usual. However, before 
the intervention, during the 6-month run-in period, several cardiometabolic risk factors 
improved significantly, including BMI, waist circumference, systolic blood pressure, heart 
rate, long-term blood glucose control, general health, and severity of illness. 
 
4.2. Strengths and limitations 
The MINT study had several strengths. First, we used a manual‐based, well‐described and 
evidence‐based theoretical framework developed by the IMPaCT team at King's College in 
London. Even though the MINT study was designed to be low budget and incorporated into 
ordinary care, the participating clinics invested considerable time and effort in the project. 
Participating in the study represented an important commitment on the part of each clinic, 
from the manager and from the health care professionals. Clinics paid for the time their staff 
spent in training and implementation, chose one professional at the clinic to act as study 
coordinator, and sent their staff to receive training in IMPaCT therapy.  
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Another strength of the MINT study was the assessment of outcome variables in the 
intervention group during the 6-month run-in period prior to the start of the intervention. A 
run-in period is common in pharmacological but not health promotion interventions. A review 
of 311 weight loss studies showed that only 19% of the studies included a run-in period; the 
highest frequency was found in pharmaceutical studies. The inclusion of a pre-randomization 
run-in period was associated with less weight loss (P = 0.0017) than the absence of a run-in 
period (Affuso et al., 2014).  
 
It is important for interventions designed to improve health behavior in people with psychosis 
to be tested in real-life settings (McGinty et al., 2016). Thus, another strength of the study was 
the real-life setting and broad inclusion criteria used in MINT, which meant that the study 
population reflected the actual population of patients at psychosis clinics in Sweden. For 
instance, potential participants were not excluded on the basis of the severity of their 
psychiatric disorder or suicidal ideation. Moreover, the multi-component design of the 
intervention gave patients the power to choose their own health priorities: every patient was 
free to choose, in dialogue with their care manager, which of the modules they wanted to 
work with. The multi-component intervention also used health care professionals and 
patients’ time efficiently. Instead of attending individual courses on treating each health 
problem, staff could attend one course on a multi-component intervention, and patients could 
participate in one program. 
 
However, the multi-component design of the intervention was also a weakness. It was not 
possible to trace the effects of each module, as all but 14 patients chose to participate in at 
least two modules. Another limitation of the study is that although the intervention manual 
recommended that participants attend a certain number of sessions, we did not measure how 
adherent they were to this recommendation.   
 
Self-reported outcomes are subject to both recall problems and social desirability bias, which 
can lead to systematic error. Recall bias in particular can be magnified in people with 
psychotic disorders. More direct measurement of physical activity (e.g., with accelerometers) 
would have been preferable. However, limited funding made it unfeasible to use such 
technology in this study. 
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Another important weakness of the study was the randomization process. The whole study 
population was not randomized into intervention and control groups. Instead, patients at the 
clinics originally participating in SMRP were assigned to the control group, and new clinics 
were recruited to provide patients for the intervention group. Patients at the newly recruited 
clinics were then randomly selected to represent the total patient population. Although the 
randomization method was not optimal, it nevertheless enabled us to assess the effects of the 
intervention. Few baseline characteristics of the intervention and control groups differed 
significantly. Thus, the choice of control group and the randomization method used to select 
the intervention group were not likely to have caused the lack of intervention effect. 
 
Finally, when designing the study, we chose to use validated instruments whenever possible. 
Many of the instruments chosen have been validated for use in psychiatric patients (Mulhern 
et al., 2014). 
 
4.3. Comparison with other studies 
Many trials that have attempted to improve the health of people with psychiatric disorders 
have focused on single risk behaviors, such as diet, smoking, or physical inactivity (Ward et 
al., 2015). The effects of such health promotion interventions in patients with schizophrenia 
have been positive in some cases (Kimhy et al., 2015; Pajonk et al., 2010; Scheewe et al., 
2013), although most have been limited (Gates et al., 2015). Weight-loss and exercise 
programs have been the most common interventions, and a meta-evaluation showed that 
several trials had positive outcomes (Singh et al., 2018), whereas others had mixed results 
(McGinty et al., 2016). A systematic review showed that nonpharmacological interventions 
led to less weight loss in patients with serious mental illness than in the general population. In 
patients with serious mental illness, the mean weight loss in randomized controlled trials is 
1.6 kg (95% CI, 0.3 to 2.9 kg), whereas it is 3.6 to 5 kg in the general population (Cabassa et 
al., 2010).  
   
Because smoking is common in patients with serious mental illness, it has also been an 
important target of behavioral interventions, with mixed results (Cather et al., 2017; McGinty 
et al., 2016). Smoking rates in patients with serious mental illness have declined much less 
than in those without such disorders (Cook et al., 2014).  
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Like our own intervention, other multi-component health behavior interventions have had 
little or no effect on important outcomes for people with schizophrenia and psychotic 
disorders, including cardiometabolic risk factors such as blood glucose, HbA1c, blood 
pressure, and blood lipids. For instance, the Danish CHANGE trial evaluated how care 
coordination alone, lifestyle coaching plus care coordination, or treatment as usual in adults 
with schizophrenia spectrum disorders and increased waist circumference affected 
cardiovascular risk (Speyer et al., 2016). Like the present study, the CHANGE intervention 
had no effect on cardiometabolic risk factors such as cardiorespiratory fitness, physical 
activity, weight, diet, or smoking (Jakobsen et al., 2017; Speyer et al., 2016). This is not 
entirely surprising given that most health promotion and weight loss interventions targeting 
the general population have modest effects, and people with schizophrenia and psychotic 
disorders have additional obstacles to overcome. The first report of the results of the ELIPS 
trial, another cluster-randomized controlled trial targeting health behavior in patients with 
severe mental illness, showed no effect psychosocial outcomes (Stiekema et al., 2018). At the 
time of writing, effects on somatic outcomes were not yet available. 
 
Single-component and multi-component intervention studies each have advantages and 
disadvantages. Complex interventions are often preferable in clinical practice, as they address 
multiple risk factors at the same time, but they are less straightforward to evaluate 
scientifically than single-component interventions. However, given our null findings and the 
lack of findings in similar multi-component health promotion intervention studies, we suggest 
that future studies evaluate more intense, single-component interventions. Moreover, in light 
of the modest results of many health promotion interventions in reducing the high burden of 
metabolic disease in people with schizophrenia and psychotic disorders, it might be time to 
perform trials of pharmacological interventions such as lipid-lowering medication, glucose 
lowering medication (Aldossari, 2018; Zheng et al., 2019), and medication for smoking 
cessation. It could also be relevant to carefully consider surgical interventions for obesity in 
selected patients with severe obesity who do not respond to health promotion interventions or 
pharmacotherapy. 
 
In the current study, a number of variables improved during the 6-month run-in period. The 
improvement may be the result of the observer effect (also referred to as the Hawthorn effect) 
(Goodwin et al., 2017), which occurs when people modify their behavior in response to the 
knowledge that they are being observed. For instance, when patients are included in a study, 
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they tend to increase their adherence to medication, as shown for hypertension (Gardner-Sood 
et al., 2015). The finding of a significant effect on cardiometabolic risk factors during the run-
in period is worth further investigation to see if it could be used in a structured way in clinical 
practice. 
 
Most trials of health promotion interventions do not include a run-in period prior to evaluating 
the new approach; such periods have most often been employed in studies on weight loss, 
especially those involving weight control drugs. Even so, weight change during the pre-
randomization (run-in) phase is rarely reported in obesity or other types of health promotion 
trials (West et al., 2011). Only 19% of the interventions included in a meta-analysis of 311 
obesity RCTs included a run-in period, and most of these were trials of pharmaceuticals 
(Affuso et al., 2014), possibly because the U.S. Food and Drug Administration's 1996 
Guidance for the Clinical Evaluation of Weight Control Drugs advocated that RCTs include a 
6-week behavioral weight reduction run-in period. Although all intervention types were 
associated with weight loss (mean=2.80 kg, SD=3.52), the effect of the active intervention 
was smaller in studies that included a pre-randomization run-in period (P=0.0017). 
  
The weak results of previous interventions and our finding of significant reductions in 
cardiometabolic risk factors after an open run-in period before the start of the active 
intervention underline the importance of designing studies that make it possible to distinguish 
between the observer effect and the effect of the intervention itself. During the run-in period, 
patients' expectations of treatment efficacy can alter behavior, which can lead improved 
health outcomes (Crow et al., 1999). In additon to increased patient focus on their own health 
problems and related behaviors, explanations for the significant effects observed during the 
run-in period could include more attention to patients from clinicians and effects of the 
training on clinicians' work (Aveyard et al., 2016).  
 
4.4. Conclusions 
This study adds to the growing evidence that multi-component health promotion interventions 
have limited effects on cardiometabolic risk factors in patients with schizophrenia and 
psychotic disorders. It also showed that several cardiometabolic and lifestyle variables 
improved during the run-in period. Researchers should consider including run-in periods in 
similar studies on health promotion interventions to avoid false positive results. 
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